Plain-English translation of NCT07281391 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing Direct Selective Laser Trabeculoplasty (DSLT), a laser-based eye treatment designed to lower eye pressure in patients with pigmentary glaucoma. Pigmentary glaucoma is a type of eye disease where pressure builds up inside the eye and can damage vision over time. The study will track whether this laser treatment effectively reduces eye pressure and whether patients need fewer glaucoma medications afterward.
Pigmentary glaucoma can lead to vision loss if eye pressure isn't controlled well enough with drops alone. This trial is testing whether the laser treatment can be an effective alternative or addition to medications for people with this specific type of glaucoma.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the laser treatment during an initial visit. After that, you'll return for follow-up eye exams over the next 12 months to measure your eye pressure and count how many glaucoma medications you need. The research team will track whether the laser successfully lowered your pressure and reduced your dependence on daily eye drops.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Mann Eye Institute
Collaborators
Sengi
Enrollment target
~45 participants
Started
March 2026
Primary completion
April 2027
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Melissa Wright
Mann Eye Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.